Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy
Man Chen, Minjing Fu, Aixian Wang, Xueying Wu, Junyi Zhen, Meiwei Gong, Xian Zhang, Guanlan Yue, Qing Du, Wei Zhao, Yanli Zhao, Peihua Lu, Hui Wang
Abstract
ClinicalTrials#: ChiCTR-IIh-16008711.gov: NCT03173417. Registered 30 May 2017 - retrospectively registered, https://www.clinicaltrials.gov/.
Topics & Concepts
MedicineMinimal residual diseaseHematopoietic stem cell transplantationCD19Internal medicineOncologyTransplantationRefractory (planetary science)CD20Flow cytometryLeukemiaImmunologyLymphomaBiologyAstrobiologyCAR-T cell therapy researchAcute Lymphoblastic Leukemia research